Display options
Cite
de la Rosa RE, Tucci JR. Intravenously administered pamidronate for treating refractory Paget's disease of bone. Endocr Pract. 1997;3(4):214-8doi: 10.4158/EP.3.4.214.
de la Rosa, R. E., & Tucci, J. R. (1997). Intravenously administered pamidronate for treating refractory Paget's disease of bone. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 3(4), 214-8. https://doi.org/10.4158/EP.3.4.214
de la Rosa, R E, and Tucci, J R. "Intravenously administered pamidronate for treating refractory Paget's disease of bone." Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 3,4 (1997): 214-8. doi: https://doi.org/10.4158/EP.3.4.214
de la Rosa RE, Tucci JR. Intravenously administered pamidronate for treating refractory Paget's disease of bone. Endocr Pract. 1997 Jul-Aug;3(4):214-8. doi: 10.4158/EP.3.4.214. PMID: 15251792.
Copy Download .nbib Format: NLM
Share it on

Endocr Pract. 1997 Jul-Aug;3(4):214-8. doi: 10.4158/EP.3.4.214.

Intravenously administered pamidronate for treating refractory Paget's disease of bone.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

R E de la Rosa, J R Tucci

Affiliations

  1. Roger Williams Medical Center, Providence, Rhode Island 02908-4735, USA.

PMID: 15251792 DOI: 10.4158/EP.3.4.214

Abstract

OBJECTIVE: To report our experience with the use of intravenously administered pamidronate in 16 patients with refractory Paget's disease of bone.

METHODS: We describe our treatment regimen and outline serum alkaline phosphatase levels at baseline and after pamidronate therapy in our study cohort. In addition, we summarize clinical symptoms and response to treatment.

RESULTS: Although clinical experience with pamidronate in the treatment of Paget's disease of bone has been limited in the United States, elsewhere it has been shown to be an effective agent that inhibits the increased osteoclastic activity characteristic of this disease. Accordingly, in 16 patients with Paget's disease unresponsive to various other therapies, we administered pamidronate intravenously at a dose of 30 mg in 500 mL of 5% dextrose in water during a 4-hour period once weekly for 6 weeks. Serum alkaline phosphatase was determined at baseline and at regular intervals for at least 12 months after the onset of therapy. Many of these patients reported relief of pain and an increased flexibility or range of motion after treatment. The only adverse effect reported by these patients was an acute-phase reaction during the first infusion in two patients. In all patients, serum alkaline phosphatase levels declined, and significant (P = 0.0012) decreases from baseline were noted within 6 weeks after the initial infusion. Maximal responses were generally seen within 6 months after treatment, serum alkaline phosphatase levels decreasing as much as 91% from baseline.

CONCLUSION: These data suggest that intravenous pamidronate therapy is an effective alternative to calcitonin and etidronate in the treatment of Paget's disease of bone, particularly in those patients refractory to such agents.

Publication Types